Skip to contentM
Medifast Inc
M
MEDMedifast Inc Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$119.00M$119.00Mderived−37.7% vs Q4 2023 Net Income$800.00K$800.00Kderived−86.7% vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Medifast Inc · CIK 910329 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$88,219,000−37.6% Operating Incomederived$708,000−91.8% Operating Cash Flowderived-$4,947,000N/M Free Cash Flowderived-$7,232,000N/M Margins · derivedGross margin74.1%+0.1 pt vs Q4 2023
Operating margin0.6%−3.9 pt vs Q4 2023
Net margin0.7%−2.5 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 18, 2025 · 49 d after period end